Power Index Rank #163
Novo Nordisk
COMPANY · Entity tracked in the LeadersCartel Power Index
1
/ 100
DOMINANT
0
High Signals
2
Emerging
0
Watch
0
Weak
Intelligence Brief
Novo Nordisk holds a monitored position in the LeadersCartel Power Index at rank #168 with a score of 0.7/100. Signal intelligence tracks Novo Nordisk across 30 sources with 0H/2E/0W active signal distribution.
Key developments include: Novo's double departures: As GLP-1 luminary retires, an obesity leader goes to B, and Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss dru.
Novo Nordisk maintains significant linkage with Eli Lilly, Lumentum, OPEC across shared intelligence signals.
Analysis updated April 12, 2026 at 08:00 UTC · Powered by RAVEN
Influence Sectors
Trade
Active Intelligence Signals
• EMERGING0.85
Nvidia AI Infrastructure Crisis: VP Reports Team Complaints Over AI Tool Limitations Despite Massive Investment; Semiconductor Sector Faces Capacity Constraints
Nvidia Vice President acknowledged that teams heavily integrated into AI workflows have significant complaints about tool trustworthiness and performance, even as the semiconductor giant pursues massi
• EMERGING0.65
Eli Lilly Market Share Declines as Novo Nordisk Holds Ground; Generic Weight-Loss Drugs Flood Indian Market
Eli Lilly's market share has contracted while Novo Nordisk maintains its position as generic weight-loss medications proliferate in the Indian pharmaceutical market. The competitive dynamics reflect b
Recent Intelligence
Endpoints News
Novo's double departures: As GLP-1 luminary retires, an obesity leader goes to Boehringer Ingelheim
CNBC World
Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India
BioPharmaDive
Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk